The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D
This growth underscores the substantial budgetary implications for Medicare, particularly amid ongoing policy discussions around expanding coverage of GLP-1s for weight management.
Authors
- Joseph Levy
- Kieran Allsop (ORCID: https://orcid.org/0000-0002-6955-914X)
- Minji Kim (ORCID: https://orcid.org/0000-0003-3340-8603)
Institutions
- Kennedy Krieger Institute (US)
- Johns Hopkins University (US)
Publication Details
- Journal
- Health Services Research
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1111/1475-6773.70098
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00